JY BioMed's GDT cell therapy reduced glioblastoma (GBM) tumor signal to undetectable levels in a preclinical model, presented at WCP 2026 in Melbourne. Discover how this Taiwan–U.S. biotech value chain advances next-generation brain cancer immunotherapy. Read more.